Equol and Vascular Function in Women With Chronic Kidney Disease

The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. Equol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the effect of 12 weeks of oral equol supplementation on vascular function in postmenopausal women with CKD.

NCT Number	NCT07194590
Lead Sponsor	University of Colorado, Denver Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions	Chronic Kidney Disease (Stage 3-4), Vascular Function, Cognitive Functions, Cerebrovascular Function, Blood Pressure
Enrollment	74 participants
Start Date	2026-02-19
Primary Completion	2030-11-30 (estimated)
Study Completion	2030-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-02